Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Build A Bear Workshop Inc (BBW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Build A Bear Workshop Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.9 (market cap $4.49B), while Build A Bear Workshop Inc trades at $30.09 (market cap $388.91M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 11.5× Build A Bear Workshop Inc's market cap, and Build A Bear Workshop Inc pays a 2.97% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | BBW | |
|---|---|---|
Market Cap | $4.49B | $388.91M |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $75.85 |
52-Week Low | $20.06 | $29.84 |
Enterprise Value | $3.69B | $488.35M |
Dividend Yield | — | 2.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Build-A-Bear Workshop (BBW) trades at $31.02, down 1.52% on the day, with a bearish technical signal despite recent earnings beats. The stock shows attractive valuation metrics, including a P/E of 7.26 and a P/S of 0.76, alongside strong profitability with a net income margin of 10.48%. Recent developments include a CEO transition to Chris Hurt and the declaration of a $0.23 quarterly dividend payable in July 2026.
The long-term outlook is supported by a debt-free balance sheet, international expansion, and a 72.73% analyst buy rating with a $62.50 consensus price target, implying significant upside. Near-term risks include consumer spending pressures and revenue guidance reductions, but the fundamental setup remains attractive for recovery in the latter half of the year.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Build A Bear Workshop Inc
Build-A-Bear is a global retailer specializing in customizable stuffed animals. It offers an interactive make-your-own experience where customers choose, stuff, and dress their furry friends in-store or online.
Read more on BBW →
